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Abstract 
Acquired copy neutral loss of heterozygosity (CN-LOH) is a frequent occurrence in myeloid 
malignancies and is often associated with resistance to standard therapeutic modalities and poor 
survival. Here, we show that mutated FLT3 and JAK2 constitutive signalling confers inter (between 
chromosome) homologous recombination (iHR), a precedent for CN-LOH. Using a targeted 
recombination assay, we determined significant iHR activity in internal tandem duplication FLT3 
(FLT3-ITD) and JAK2V617F mutated cells. Moreover, sister chromatid exchanges (SCE) a surrogate 
measure of iHR was significantly elevated in primary FLT3-ITD normal karyotype acute myeloid 
leukaemia (NK-AML) compared to wild type (WT) FLT3 NK-AML. Homologous recombination (HR) is 
harmonised to S phase of the cell cycle to repair broken chromatids and prevent iHR. We 
demonstrated increased HR activity in G0 arrested primary FLT3-ITD NK-AML in contrast to WT FLT3 
NK-AML.  Lastly, using a thymidine kinase (TK) gene mutation assay, mutated FLT3-ITD transfected 
cells demonstrated a significantly increased mutation frequency compared to WT transfection and 
that TK resistance was significantly associated with CN-LOH at the TK locus. Strikingly, treatment of 
FLT3-ITD and JAK2V617F mutant cells with the anti-oxidant, N-acetyl cysteine diminished reactive 
oxygen species (ROS) restoring iHR and HR levels observed for WT. These findings provide a proof of 
principle that mutated FLT3-ITD and JAK2 constitutive kinase activity augments ROS production and 
HR, shifting the cellular milieu towards illegitimate recombination events such as iHR and CN-LOH. 
Therapeutic reduction of ROS thus may prevent leukemic progression and relapse in myeloid 
malignancies. 
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 Introduction  
The majority of patients with adult acute myeloid leukemia (AML) that present with a normal 
karyotype (NK-AML) are grouped together in the “intermediate” risk cytogenetic category and 
constitute 40-45% of all adult AML patients. Mutations in the FMS-like tyrosine kinase 3 (FLT3) 
receptor whether it is internal tandem duplication (ITD) of its juxtamembrane domain or point 
mutations in its kinase domain are the most frequent mutations in NK-AML(1). Constitutive 
activation of the JAK2 signalling pathway occurs in most myeloproliferative neoplasms (MPN) such 
as Polycythaemia Vera as well as in a significant proportion of other myeloid malignancies (2). Both 
FLT3-ITD and JAK2 mutations drive uncontrolled hematopoietic cell expansion. FLT3-ITD mutation 
in NK-AML predicts a more aggressive disease associated with resistance to therapy and poor 
survival. However, the prognosis for AML patients that has lost the WT FLT3 allele and acquired 
the mutated FLT3-ITD is worse compared to patients maintaining WT FLT3. Loss of heterozygosity 
through duplication of genomic material on maternal or paternal chromosomes known as copy 
neutral LOH (CN-LOH), is a chromosomal change initially described in AML by Raghavan et al (3). 
Since the discovery of CN-LOH (sometimes referred to as acquired uniparental disomy (UPD) in 
AML, recurrent regions of CN-LOH associated with homozygous mutations have been identified in 
AML (4). In addition to the CN-LOH of FLT3-ITD at 13q, CN-LOH has been demonstrated at 4q 
and 9p in the presence of homozygous mutations of TET2 and JAK2 respectively, doubling the 
oncogenic gene burden (5). Identification of multiple regions of LOH associated with mutation, 
points to a common mechanism of homozygosity in myeloid malignancies that is required for 
leukemic progression.  
It is now generally accepted that acquired CN-LOH is the result of a homologous recombination 
(HR) event (6). Mitotic HR is evoked in response to the repair of a double strand break (DSB) in 
DNA. Genomic integrity is maintained in the cell by specific DNA repair mechanisms such as HR 
and non-homologous end-joining (NHEJ). Nonetheless, defects in DNA repair can result in the 
inappropriate or abnormal repair of DNA damage resulting in propensity to malignant change. We 
have reported previously, that primary AML cells have increased NHEJ repair activity and 
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accompanying repair infidelity. Furthermore, constitutively activated N-RAS results in an increase 
in reactive oxygen species (ROS) that damages DNA and evokes a DNA damage response (7-9). 
Our findings suggest that excessive DNA damage in AML may force normal DSB DNA repair 
components to process DSB aberrantly, resulting in chromosomal instability. It has been previously 
reported that constitutive FLT3 activation results in increased ROS production, a subsequent 
increase in DSB and inaccurate repair by the NHEJ pathway (10). The authors suggested that 
genomic instability derived from constitutive FLT3 signalling generates more mutations that 
facilitate leukemic progression. However, increased NHEJ cannot account for phenomena of CN-
LOH.  
To explore the relationship between constitutive FLT3 and JAK2 signalling and the propagation of 
CN-LOH we have utilised novel recombination assays that detect HR events in mutated FLT3 and 
JAK2 cells. We show that the FLT3-ITD and JAK2V617F mutation confer increased inter (between 
chromosomes) homologous recombination (iHR) activity compared to WT kinase. Moreover, iHR 
activity was reliant on the FLT3-ITD and JAK2V617F mutation dependent elevation of ROS. NK-
AML patients with FLT3-ITD mutations also possessed significantly increased sister chromatid 
exchanges (SCE) (a surrogate for iHR activity), whilst a thymidine kinase (TK) reporter assay 
demonstrated FLT3-ITD activity preferentially increases resistance to TK through the creation of 
CN-LOH. Our results pinpoint a common pathway whereby constitutive FLT3 and JAK2 signalling 
confers iHR and the subsequent propagation of CN-LOH in normal karyotype myeloid malignancy. 
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Methods and Materials 
Patients Twenty two patients with de-novo AML and normal karyotype by metaphase 
cytogenetics were selected. The median age was 53 years (8-78 years) and the median 
white blood cells count was 51.3 x 109/l.  Primary material was obtained following written 
informed consent from patients prior to inclusion in study in accordance with the declaration 
of Helsinki by King’s College Hospital Local Research Ethics Committee. 
Drugs The FLT3 inhibitor, AC220 (Quizartinib) was purchased from Selleckchem and re-
suspended in PBS. N-acetyl cysteine (NAC), Hydrogen peroxide (H2O2) and the RAD51 
inhibitor, B02 were purchased from Sigma-Aldrich, Poole UK.  
Plasmids and DNA repair substrates Human FLT3 and FLT3-ITD (18bp insertion) have 
been previously cloned into FUGW plasmid (kind gift from Feyruz Rassool, University of 
Maryland). The BAMH1-ECOR1 GFP fragment was removed from FUGW prior to cloning. 
Expression constructs, pMSCV-FLT3-WT and pMSCV-FLT3-ITD were described previously 
(11-12) and were kindly donated by Lars Rönnstrand, University of Malmo. PMSCVneo WT 
JAK2 and pMSCVneo JAKV617F (13) were kindly donated by Gary Reuther, University of 
South Florida. DNA repair substrate, DR-GFP and the I-SCEI expressing plasmid, 
pCBASCEI have been described previously by Maria Jasin’s group (14-15) and were 
purchased via the Addgene repository (DR-GFP, Addgene plasmid 26475 and pCBASCEI, 
Addgene plasmid 26477). Creation of targeted repair substrates is provided in 
supplementary methodology. 
Targeted Recombination assays To study targeted iHR, DNA repair substrates; PZD-DR1-
Puro (10g) and PZD-DR2-Blast (10g) were simultaneously transfected (Nucleofection, 
Amaxa) into 2 x 106 cells using the CompoZr Zinc finger nuclease (ZFN) targeted integration 
kit (Sigma) according to the manufacturer’s instructions. To analyse targeted HR, PZD-
DR1/DR2-Puro (20g) was transfected into 2 x 106 cells also using CompoZr ZFN. Two days 
after transfection, cells were antibiotic selected and divided into 24 well plates to isolate 
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correctly targeted clones. After 5 days, cells were collected for FISH analysis and PCR 
identification of integration at the AAVS locus. Only correctly targeted clones with PZD-DR1-
Puro and PZD-DR2-Blast were selected and expanded. To correctly targeted HEK293 
clones, 2g of WT, FLT3-ITD, JAK2V617F or empty expression vector were transfected into 
2 x 106 cells. Antibiotic selection (200g/ml Zeocin for FUGW-FLT3-ITD, 500g/ml G418 for 
pMSCVneo-JAK2V617F) were added 24h after transfection in fresh media. Relative 
expression of FLT3 and JAK2 was determined by quantitative PCR and western blotting 3 
days after antibiotic selection. 10l of the I-SCEI expression viral supernatant was added to 
PZD-DR1-Puro and PZD-DR2-Blast targeted cells and cultured for a further 5 days before 
FACS analysis. For simultaneous drug additions, 10-50nM AC220 or 5mM N-acetyl cysteine 
(NAC) were added for 24h prior to addition of I-SCEI. To account for variation in transfection 
efficiencies between test cells, the targeted recombination % for each test was made relative 
to the transfection of PZD-GFP-Puro GFP expression.  
Cell Lines The leukemic cell lines, MOLM-13, U937, and the embryonic kidney cell line, 
HEK293 were obtained from the DSMZ. The lymphoblastic cell line, TK6 was obtained from 
the ATCC. These cell lines were purchased within the last three years, propagated, 
expanded, and frozen immediately into numerous aliquots after arrival. The cells revived 
from the frozen stock were used within 10–15 passages and not exceeding a period of 6 
months. The DSMZ and ATCC use morphological, cytogenetic and DNA profile analysis 
such as STR fragment analysis for characterization and authentication of cell lines. Prior to 
the study start, all cell lines were subjected to mutation analysis using Roche 454 parallel 
sequencing for authenticity compared to the genotype characterised by the DSMZ and 
ATCC.   
PCR confirmations To confirm specificity of targeted integration 5 days after transfection, 
DNA was prepared from transfected cells (Qiagen). Site specific PCR was carried using the 
CompZr AAVS forward primer and a reverse primer specific to PZD-DR1-Puro and PZD-
DR1/DR2-puro, (5’-CTT GTA CAG CTC GTC CAT GC) and to PZD-GFP-puro and PZD-
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DR2-Blast, (5’-CAG TGC AGG AAA AGT GGC ACT). PCR was carried out according to the 
CompZr integration PCR protocol using Roche Expand High Fidelity PLUS polymerase. To 
confirm the recombination at the I-SCEI site, recombined GFP positive cells were FACS 
sorted (FACSaria, Beckman Coulter) into 96 well plates to collect GFP positive cells. Cells 
were used for hot start PCR across the DR1 region using forward primer: CTG CTA ACC 
ATG TTC ATG CC and reverse primer:  AAG TCG TGC TGC TTC ATG TG. The PCR 
product was digested with 10U of I-SCEI or 10U BCG1. GFP positive PCR products 
attributable to HR should be I-SCEI un-digestible and BCG1 digestible. Products were 
loaded onto gels and stained with ethidium bromide, and the ethidium signals for the 
enzyme-resistant and enzyme-cleaved band were quantified by using Adobe Photoshop 
software. 
Fluorescent hybridisation (FISH) PZD targeting vectors were fluorescently tagged for 
FISH studies using the Fasttag labelling kit (Vector, Burlingame CA). 10g of vector and was 
denatured at 95C for 30min in the presence of Fasttag reagent. Vectors were subsequently 
coupled with either fluorescein or Texas Red maleimide. Labelled vector DNA was 
determined to be between 100-400bp by agarose gel electrophoresis. Metaphase spread 
chromosomes were prepared as stated for the analysis of sister chromatid exchanges.  After 
the slides were dried overnight, the slides were spotted with 200l ethanol and placed on a 
hotplate for 20min. The slides were then cooled and immersed in 2% SSC for 20min before 
dehydration in an ethanol series (70%, 85%, and 100%). Fluorescently labelled vector was 
diluted to 1ng/l in hybridisation buffer (60% deionized formamide, 2 X SSC, 10% dextran 
sulfate, 50mM sodium phosphate pH7). The fluorescently labelled vector was denatured at 
75C for 5 min prior to addition to the slide and sealing with rubber cement. The slide was 
then denatured on a hotplate for 4min at 75C. Slides were then placed in humid boxes 
overnight at 37C. After hybridisation, slides were blocked in blocking solution (5% non-fat 
dry milk plus 0.1% tween 20 in 4 X SSC) for 60min at 37C. The slides were then washed in 
blocking solution and subsequently incubated in biotinylated anti-fluorescein or anti-Texas 
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Red (10g/ml) in blocking solution for 30min at RT. Slides were washed again 3 times in 
blocking solution and then incubated in fluorescein or Texas Red Avidin solution (10g/ml) 
for 30min at RT. Slides were washed in 4 x SSC + 0.1% tween 20 (2 x 5min) before staining 
with DAPI (100g/ml) for 5 min and mounting in vectashield. SureFish 19q 13.11 CEBPA 
probe (Agilent) was used as a control for vector targeting the AAVS1 locus. Hybridisation of 
probe was as manufacturer’s instructions. Slides were visualized using a Leica epi-
fluorescent microscope, and images were captured using a CCD camera and Leica LAS AF 
software. Two slides were prepared for each experiment. 
TK6 assay The lymphoblastoid cell line, TK6 was cultured in CHAT media (10M 
deoxycytidine, 200M hypoxanthine, 0.1M aminopterin and 17.5M of thymidine) for 3 
days to reduce the background mutant fraction. TK6 were then transfected with empty 
vectors, FUGW and pMSCV or FUGW WT-FLT3, FUGW FLT3-ITD selected in 200g/ml 
Zeocin or pMSCV-WT-FLT3 and pMSCV-FLT3-ITD selected in 1g/ml puromycin for 24h 
and then cultured for 5 days. To determine the mutation rate, 2 X 105 cells was seeded into 
ClonaCell™-TCS Medium (Stem Cell Technologies, France) with and without 2g/ml 
trifluorothymidine (TFT) and incubated for a further 10 days. The mutation frequency was 
calculated by dividing the number of colonies on TFT containing plates by the number of 
colonies on the plates without TFT. Triplicate plates for all tests were produced. The 
mutation rate was determined by seeding 2 X 105 cells into 25 wells of media containing TFT 
and determining the fraction of wells without TFT resistance. The Mutation Rate was 
calculated using the Fluctuation test originally described by Luria and Delbrück (17) using 
the formula.  
 
 
(ln - natural log, h – Number of wells without resistance/number of wells, n – number of cells) 
Additional methods can be found in supplementary methodology  
Mutation Rate = -ln x   h 
  n 
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Results 
Development of a Zinc Finger Nuclease (ZFN) targeted assay for the determination 
of iHR  
We firstly developed a novel reporter assay targeted to chromosome 19q using CompoZr 
Zinc finger nuclease (ZFN) to detect iHR (Figure 1A-D). The assay, based on the DR-GFP 
reporter developed by Jasin et al, relies on the sequential targeting of two overlapping, but 
disrupted GFP repeat sequences to separate alleles at the adeno associated virus 
integration site 1 (AAVS1) locus (14-16). The two GFP repeat sequences, 5’GFP and 3’GFP 
were individually cloned into the targeting vectors, PZDonor-AAVS1 Puromycin (Figure 1 
A,C and PZDonor (Figure 1 B,D) respectively to create PZD-DR1-Puro and PZD-DR2-Blast 
respectively. PZD-DR1-Puro and PZD-DR2-Blast can be sequentially targeted to AAVS1 on 
separate 19q alleles with concomitant transfection with AAVS1 specific ZFN. iHR and 
subsequent gene conversion between the disrupted GFP sequences would result in GFP 
expression. To test the specificity of ZFN targeting, we initially cloned the full length intact 
GFP into PZDonor-AAVS puromycin and transfected this vector with AAVS1 specific ZFN 
into HEK293 cells. Supp. Figure 1A-B shows correct integration of PZD-GFP-Puro into the 
AAVS1 locus using locus specific primers and FISH. Integration efficiency before antibiotic 
selection was between 10-15% for cell lines (data not shown). Without ZFN transfection, 
there was no AAVS1 integration and no puromycin resistant cells after selection. Targeted 
integration of PZD-DR1-Puro and PZD-DR2-Blast to the AAVS1 locus was performed in the 
FLT3-ITD mutated cell line, MOLM-13 (known hereon as MOLM-13PZD), the WT FLT3 
U937 (known hereon as U937PZD) and HEK293 (known hereon as HEK293PZD). Targeted 
integration was confirmed using locus specific PCR and FISH (Figure 1 E-G). Clones with 
both the correct integration of PZD-DR1-Puro and PZD-DR2-Blast to separate AAVS1 loci 
were then expanded in culture.  
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FLT3-ITD cells demonstrate iHR  
FLT3-ITD expressing cells were tested for iHR events using the targeted iHR reporter assay. 
MOLM-13PZD and FLT3-ITD transfected HEK293PZD cells demonstrated reproducible GFP 
positive cells in three separate experiments (iHR events, 0.15% and 0.25% respectively 
compared to U937PZD, WT-FLT3 and empty vector transfected HEK293PZD cells (0%, 
p<0.05, n=3) (Figure 1H, Table I). Induction of iHR in FLT3-ITD transfected HEK293PZD 
corresponded to a 4-fold increase in RAD51 expression after normalisation for FLT3 
overexpression (Supp. Figure 2A). Pre-treatment of MOLM-13PZD and FLT3-ITD 
transfected HEK293PZD cells with the FLT3 inhibitor, AC220 down-regulated RAD51 
expression with the concomitant abolition of iHR events (Figure 1H, Supp. Figure 2 B-C, 
Table I). Furthermore, iHR were also eliminated with pre-treatment with the anti-oxidant, N-
acetyl cysteine (NAC) (Table I, Supp. Figure 2B). Interestingly, iHR events were significantly 
dependent on both HR activity and ROS as pre-treatment of MOLM-13PZD and FLT3-ITD 
transfected HEK293PZD cells with the RAD51 inhibitor, B02 abolished iHR events, but 
addition of the pro-oxidant, hydrogen peroxide (H2O2) increased iHR events (Table I, Supp. 
Figure 2B). To verify that GFP positive cells in this assay were the result of iHR and not false 
positives, hot start PCR using primers designed at the DR1 locus was carried out on FACS 
sorted GFP positive cells. PCR products from GFP positive cells could only be digested by 
BCG1 and not I-SCEI confirming the presence of iHR dependent GFP positive cells (Figure 
1 I-J). GFP positive cells were also verified using fluorescence microscopy (Supp. Figure 
2D). 
 
FLT3-ITD mutation increases HR events in primary NK-AML 
Increased HR has been shown previously in FLT3-ITD AML (17). To investigate further the 
presence of elevated HR as the catalyst for iHR in primary FLT3 mutated AML, we 
measured targeted single locus HR in a cohort of NK-AML. Primary NK-AML (n=22) were 
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initially characterised by SNP-A and DNA sequencing (Supp. Table I). 15/22 primary NK-
AML had FLT3-ITD mutations with a clone size ≥ 25%. 7/22 primary NK-AML were WT for 
FLT3, but had nucleophosmin (NPM1) and DNA methyltransferase 3 (DNMT3a) mutations. 
We developed a novel HR reporter assay, using the HR substrate, PZD-DR1/DR2-Puro that 
possesses two disrupted, but overlapping GFP sequences targeted to AAVS1 (Supp. Figure 
3A, supplementary information). HR between the two sequences would result in GFP 
expression. PZD-DR1/DR2-Puro was transfected into primary FLT3-ITD with CompoZr 
ZFN. Supp. Figure 3B-D shows correct integration of PZD-DR1/DR2-Puro into the AAVS1 
locus using locus specific primers and FISH.  Clones with the correct integration of PZD-
DR1/DR2-Puro AAVS1 were further transfected with an I-SCEI expression viral supernatant 
to introduce a double strand break in the integrated PZD-DR1/DR2-Puro and induce 
recombination. PZD-DR1/DR2-Puro/I-SCEI transfected primary FLT3-ITD (n=4) 
demonstrated significantly increased HR activity compared to primary WT FLT3 (n=2), (1.2 
vs 0.25%, p<0.01) (Figure 2A, Supp. Table II). The increased HR activity was not 
attributable to elevated I-SCEI expression in primary FLT3-ITD after lentiviral transduction, 
but minimal cytotoxicity was noted at high I-SCEI concentrations in all primary cells that did 
not affect recombination rates (Supp. Figure 4A). All measurements of PZD-DR1/DR2-Puro 
HR events were made relative to transfection of PZD-GFP-Puro + ZFN to correct for variable 
transfection efficiencies in primary AML. Integration efficiency before antibiotic selection was 
between 5-15% for primary cells (Supp. Figure 4B). Pre-treatment of primary cells with 
AC220 or NAC significantly inhibited HR events (1.2 vs 0.1%, p<0.01)(Figure 2A, Supp. 
Table II). Moreover, PZD-DR1/DR2-Puro/I-SCEI transfected MOLM-13 and U937 + FLT3-
ITD also exhibited increased targeted HR that was inhibited with AC220 or NAC (mean 
across all groups, 2.6 vs 0.35%, p<0.01) (Supp. Table III, Supp. Figure 4 C-D). Inhibition of 
HR in primary NK-AML correlated with the reduction in RAD51 expression with AC220 
(Figure 2B).  Expression of HR repair factors, MRE11 and CTiP were not affected by AC220, 
but the expression of cyclin dependent kinase inhibitor, p21 was abrogated as previously 
shown by Raderschall et al (18). FLT3-ITD expression also resulted in the phosphorylation 
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of both AKT and STAT5 in primary NK-AML and FLT3-ITD transfected HEK293 that was 
also abrogated upon AC220 pre-treatment (Figure 2 B-C). Mononuclear cells from this 
cohort of primary NK-AML, MOLM-13 and FLT3-ITD transfected U937 were also cultured 
and assessed for their ability to localise phospho-H2AX and RAD51 as a measure of DSB 
DNA damage and HR activity respectively. Immunofluorescence studies showed that 
primary AML with FLT3-ITD, MOLM-13 and FLT3-ITD transfected U937 cells have increased 
mobilization of phospho-H2AX and RAD51 compared to WT FLT3 primary AML cells and 
U937 transfected with WT FLT3 (Mean for all groups; RAD51, 21% vs 10.3%, p<0.01; 
phospho-H2AX 17 vs 12.7%, p<0.01, n=3) (Figure 2 D-E, Supp. Figure 5 A-C).  Pre-
treatment of cells with NAC significantly inhibited both RAD51 foci formation (21 vs 14%, 
p<0.01) as well as phospho-H2AX foci (17 vs 11.6%, p<0.05). Moreover, there was a direct 
correlation between the increased RAD51 and phospho-H2AX foci and the augmentation of 
ROS for FLT3-ITD positive NK-AML (Figure 2 E-F, Supp. Figure 5 A-E).  
 
Primary AML with FLT3-ITD mutations demonstrate increased sister chromatid 
exchanges (SCE) 
Given the increased HR in mutated FLT3 cells, recombination or ‘crossing over’ is likely to 
occur between chromatids following DNA breakage. This phenomenon is known as sister 
chromatid exchanges (SCE). Inadvertent slippage of a broken chromatid could result in the 
use of its homologous chromosome for repair, supporting the utility of SCE analysis as a 
surrogate for iHR. To confirm the presence of elevated recombination in primary FLT3 
mutated AML, we measured SCE in 22 NK-AML. FLT3-ITD primary AML, MOLM-13 and 
FLT3-ITD transfected U937 cells show a significant increase in SCE compared to WT FLT3 
primary AML and WT FLT3 transfected U937, (mean across groups, 9.9 vs. 5.5 SCE per 
metaphase, p<0.001) (Figure 2 G-H, Supp. Fig. 6A-C, Supp. Table II and III). Moreover, 
treatment of FLT3-ITD primary AML, MOLM-13 and FLT3-ITD transfected U937 cells with 
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the AC220 or NAC restored SCE to levels observed for WT FLT3 (mean across groups 
AC220: 9.9 vs. 5.9 SCE per metaphase, p<0.05; NAC: 9.9 vs 6.7 SCE, per metaphase, 
p<0.05). 
 
JAK2V617F mutation increases targeted iHR events  
Constitutive activation of the JAK2 signalling pathway occurs in most myeloproliferative 
neoplasms (MPN) such as Polycythaemia Vera as well as in a significant proportion of other 
myeloid malignancies. JAK2 mutations such as V617F give rise to a proliferative phenotype 
that has also shown to induce increased ROS production (19). As JAK2V617F is associated 
with CN-LOH on chromosome 9p in MPN we determined whether JAK2 and FLT3 mutations 
share a common mechanism in initiating CN-LOH. The JAK2V617F mutated leukemic cell 
line, HEL and JAK2V617F transfected HEK293 demonstrated 4 fold increased RAD51 
expression compared to U937 and WT JAK2 transfected HEK293 (Figure 3 A-B). 
JAK2V617F expression also resulted in the phosphorylation of both AKT and STAT5 in 
JAK2V617F transfected HEK293. Targeted integration of PZD-DR1-Puro and PZD-DR2-
Blast to the AAVS1 locus was performed in the JAK2V617F mutated cell line, HEL (known 
hereon as HELPZD) and showed significant iHR events compared to U937PZD (0.2% vs 
0%, p<0.05, n=3)(Figure 3C). Furthermore, we were able to abolish iHR events with NAC. 
HEK293PZD cells were transfected with JAK2V617F and also demonstrated reproducible 
GFP positive cells (iHR events, 0.3% compared to WT JAK2 and empty vector transfected 
HEK293PZD cells (0.3% vs 0%, p<0.05, n=3) (Table I). We also show that HEL and 
JAK2V617F transfected HEK293 cells demonstrate increased HR compared to HEK293 + 
WT JAK2 (2.6% vs 1%, p<0.05, n=3) and that ROS is significantly elevated in JAK2V617F 
cells (Figure 3 D-F). 
 
Inappropriate RAD51 expression and HR activity in G0 arrested FLT3-ITD cells.  
14 
 
RAD51 expression is tightly regulated in normal cells with the highest expression being at 
S/G2 phases during and after DNA replication and its lowest expression at G0/G1 phases or 
in non-dividing cells (6). As FLT3-ITD mutation results in significantly overexpressed RAD51 
we investigated whether there was inappropriate expression of RAD51 in FLT3-ITD mutated 
cells outside of S/G2 that may result in recombination between homologous chromosomes 
rather than between identical chromatids after replication. Primary NK-AML and MOLM-13 
cells were initially cultured in full growth media and then in the absence of foetal calf serum 
for 3 days. G0 arrested primary FLT3-ITD NK-AML and G0 arrested and FACS sorted MOLM-
13 demonstrated increased RAD51 foci localisation and low, but consistent RAD51 
expression compared to G0 arrested primary WT FLT3 AML and G0 arrested FACS sorted 
U937 cells (Figure 4 A-D, Supp. Fig. 7A-F). Strikingly, G0 arrested WT FLT3 primary AML 
and G0 arrested U937 cells only exhibited RAD51 expression 12h after culture stimulation 
with growth factors. Transfection of the HR substrate, PZD-DR1/DR2-Puro and subsequent 
induction of a DNA DSB by I-SCEI transfection showed that G0 arrested FACS sorted 
MOLM-13 demonstrated low, but reproducible HR events compared to G0 arrested FACS 
sorted U937 cells. Furthermore, G0 MOLM-13 HR events were abolished with co-culture with 
AC220 or NAC (Figure 4G).  
 
FLT3-ITD mutation promotes CN-LOH over hemizygosity at the thymidine kinase 
(TK) locus  
The human lymphoblastic cell line, TK6 possesses heterozygous frameshift mutations in 
exon 4 and exon 7 of thymidine kinase (TK) (20). Loss of heterozygosity (LOH) at this locus 
renders resistance to trifluorothymidine (TFT). We exploited LOH at the TK locus to study 
the effects of mutant FLT3-ITD expression. TK6 cells were transfected with FLT3-ITD or WT 
FLT3 or empty vectors and subsequently cultured in TFT to allow the generation of TK 
mutations. Figure 5A and Supp. Table IV show that spontaneous TK mutation rate and 
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frequency were significantly elevated in FLT3-ITD transfected TK6 clones compared to WT 
FLT3 and empty vector transfected TK6 clones. We demonstrated this mutation phenotype 
using 2 different FLT3-ITD expressing vectors (FUGW and pMSCV). Strikingly, for both 
FLT3-ITD expressing vectors, mutant rate and frequency were significantly ameliorated with 
addition of AC220 or NAC. To determine the type of LOH if any at the TK locus, clones from 
FLT3-ITD, WT FLT3 and empty vector controls were used for fragment PCR analysis. More 
than 20 TK deficient clones were analysed per group. Figure 5B-C demonstrates that in 
FLT3-ITD transfected TK6 mutants, more than 50% of clones exhibited homozygous LOH at 
the TK locus in contrast to empty vector controls. The remaining 50% in FLT3-ITD 
transfected TK6 gave no LOH, whilst hemizygous LOH was not observed. Significantly, CN-
LOH frequency at the TK locus was inhibited with concomitant addition of AC220 (55 vs 
28%, p<0.01) and NAC (55 vs 26%, p<0.01). Microsatellite analysis of the q arm of 
chromosome 17 was also used to confirm CN-LOH in TK mutants. Nine microsatellites were 
chosen, 8 located to the q arm and one to the p arm.  From 34 TK resistant colonies derived 
from FLT3-ITD transfected TK6 clones, we determined 3 sizes of CN-LOH all extending to 
the telomere (Figure 5D). FLT3-ITD transfected TK mutants demonstrating homozygous 
LOH at the TK locus establishes an enhanced propensity of such mutations to confer CN-
LOH and can abrogated through inhibition of constitutive FLT3 activity or anti-oxidant 
treatment.  
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Discussion 
Oncogenes such as FLT3 and JAK2 play key roles in hematopoietic stem cell proliferation, 
differentiation and survival (21-23). Mice that are heterozygous for the FLT3-ITD mutation 
develop a chronic myeloproliferative disease and must acquire other mutations or cellular 
changes to develop the full AML phenotype. Other molecular changes must also occur to 
allow the spontaneous loss of heterozygosity in these oncogenes that increases the severity 
of AML. Since our original report detailing CN-LOH in low risk myelodysplastic syndrome 
(24) there have been a plethora of reports documenting the prevalence of CN-LOH in a 
number of other hematological disorders (reviewed by O’Keefe et al, 4). Furthermore, we 
and others have associated microsatellite instability (MSI) as an instigator of CN-LOH (25-
26).  However, the aetiology of CN-LOH acquisition remains unknown. In this report, we 
provide comprehensive evidence of a common mechanism of CN-LOH in NK-AML where 
excessive ROS derived DSB DNA damage is preferentially repaired by mutant FLT3 or 
JAK2 dependent elevation in iHR and HR. 
ROS has been previously shown to be elevated by mutant FLT3 (10), JAK2 (19) and BCR-
ABL (27) resulting in DNA damage, genomic instability and leukemic progression. Indeed, 
we have previously demonstrated that a constitutively activated mutant N-RAS mouse model 
augments ROS production resulting in DSB DNA damage and subsequent up-regulation of 
NHEJ repair activity.  Mice fed with the anti-oxidant, N acetyl cysteine (NAC) demonstrated a 
significant reduction in ROS, diminished DNA damage and NHEJ activity (9). We 
demonstrate here that mutant FLT3 and JAK2 confer augmented ROS species that induce 
DNA damage resulting in both mutations and chromosomal instability as observed in the TK 
assay that can be abolished with pre-treatment with anti-oxidants. Such genomic instability is 
the prerequisite for leukemic progression. Interestingly, Both STAT5 and AKT were both 
phosphorylated in FLT3-ITD and JAK2V617F cells.  STAT5 dependent activation of NADPH 
oxidase in association with RAC1 results in increased ROS, whilst AKT activates FOXO3 to 
17 
 
abrogate catalase (inhibitor of ROS) (28). A contribution of both pathways is likely to provide 
the high levels of ROS to drive genomic instability and leukemic progression.  
Repair of DSB requires the co-ordinated actions of both NHEJ and HR to insure genomic 
fidelity and negate chromosomal aberrations. NHEJ is the predominant mammalian pathway 
being active throughout the cell cycle, whilst HR is primarily active during S phase during 
DNA replication. Aberrant interplay between these repair activities has a profound effect on 
DNA repair and genomic fidelity. In accordance with other reports, mutant FLT3 and JAK2 
demonstrated increased RAD51 expression resulting in exaggerated HR activity through the 
binding of phosphorylated STAT5 to the RAD51 promoter (29). It is notable, that mutant 
FLT3 and JAK2 are associated with CN-LOH at their respective loci resulting in a more 
aggressive phenotype. Similarly, mutant TP53 that is also associated with CN-LOH at 17p 
demonstrates increased RAD51 expression and HR activity (29). The elevated HR activity 
not only results in increased resistance to traditional chemotherapy, but could also drive the 
propagation of iHR.  Here, we provide a model where FLT3-ITD and JAK2V617F dependent 
constitutive activity drives the propagation of CN-LOH that can be prevented with anti-
oxidant treatment (Figure 5E). Mutated FLT3 or JAK2 drives the accumulation of ROS that 
damages DNA and is preferentially repaired by FLT3-ITD and JAK2V617F dependent 
augmentation of the HR repair pathway,that increases SCE and also the likelihood of 
increased iHR events. A specific iHR event at 13q for FLT3 or 9p for JAK2 would result in 
the doubling of mutant gene dosage and selection for malignant progression.  However, the 
observed overactive HR may not by itself be sufficient to confer iHR. To this end, we also 
demonstrate inappropriate expression of HR activity in G0 cells in primary FLT3-ITD cells. 
HR is tightly regulated to be active after DNA replication to repair broken chromatids. Breaks 
in one chromatid can be accurately repaired using its identical sister by HR.  Prior to DNA 
replication in G1, NHEJ repairs DSB, however, illegitimate HR expression in G1 has the 
capacity to repair breaks between homologous chromosomes resulting in iHR events and 
CN-LOH. Further, we show that mutated FLT3 also confers increased expression of the 
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cyclin dependent kinase inhibitor; p21 in primary NK-AML; mediating G1 arrest and slower 
progression to S phase increasing the likelihood for iHR.  
The proposal that CN-LOH is not merely a stochastic event brought about by selection 
pressure of a leukemic clone, but a direct result of constitutional FLT3 and JAK2 activity has 
considerable relevance to the biology and therapy of myeloid malignancies. The disparate 
and independent activities of a single oncogene having the capacity to combine to create 
CN-LOH may be a common mechanism in these diseases. The identification of this 
mechanism of CN-LOH propagation will also open up further avenues of investigation. The 
TK assay revealed a bias in FLT3-ITD transfected cells to specific sites and sizes of CN-
LOH. The uniformity of the CN-LOH suggests that common breakpoints at the TK locus were 
responsible for the CN-LOH. Similarly, CN-LOH at 13q may be a reflection of hotspots of 
recombination at the locus rather than simply a selection of a mutant FLT3 homozygous 
clone. Targeting integration of DNA repair substrates at CN-LOH rich loci could be utilised to 
determine preferential sites of recombination and their correlation to fragile sites. ROS 
induced DNA damage has been postulated to induce mutations to accelerate leukemic 
progression and relapse (9). The present study makes a valid case for the use of anti-
oxidants in haematological malignancy given the observed ROS accumulation in CML, AML, 
MPN and CLL (30). Such treatments working alone or in combination with conventional 
therapies could prevent the accumulation of mutations and the acquisition of CN-LOH in NK-
AML slowing the rate of disease progression. Furthermore, the side-effects of using high 
dose DNA damaging chemotherapy could be avoided if low doses can be combined with 
anti-oxidants. Our findings suggest that novel therapies targeting the generation of ROS 
would prove to be of great importance clinically for treatment of mutant FLT3 and JAK2 
myeloid malignancies.  
  
19 
 
Acknowledgements 
 
This work was funded by Kings College Hospital. 
 
 
  
20 
 
References 
1. Martelli MP, Sportoletti P, Tiacci E, Martelli MF, Falini B. Mutational landscape of AML 
with normal cytogenetics: biological and clinical implications. Blood Rev. 2013;27:13-22. 
2. Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in 
hematological malignancies. Biochem Pharmacol. 2006;71:713-21 
3. Raghavan M, Smith LL, Lillington DM, Chaplin T, Kakkas I, Molloy G, et al. Segmental 
uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid 
leukemia. Blood. 2008;112:814-21 
4. O'Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel 
chromosomal lesion in myeloid malignancies. Blood 2011;115:2731-9. 
5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-
function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-90. 
6. Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA double-strand break 
repair pathway choice. Mol Cell. 2012;47:497-510 
7. Gaymes TJ, Mufti GJ, Rassool FV The Non Homologous End-Joining Pathway is Aberrant 
in Human Myeloid Leukemias: Evidence that KU70/86 is required for the Increased 
Frequency of Misrepair.  Canc. Res. 2002;62:2791-2797. 
8. Brady N, Gaymes TJ, Cheung M, Mufti GJ, Rassool FV Increased Error-prone NHEJ 
Activity in Myeloid Leukemias Is Associated with DNA Damage at Sites that Recruit Key 
Nonhomologous End-Joining Proteins. Cancer Res. 2003;63:1798-1805. 
9. Rassool FV, Gaymes TJ, Omidvar N, Brady N, Beurlet S, Pla Reactive oxygen species, 
DNA damage, and error-prone repair: a model for genomic instability with progression in 
myeloid leukemia? Cancer Res. 2007;67:8762-71. 
21 
 
10. Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, Shapiro P, et al. Internal tandem duplication 
of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: 
implications for poor prognosis in AML. Blood. 2008;111:3173-82. 
11. Heiss E, Masson K, Sundberg C, Pedersen M, Sun J, Bengtsson S, Rönnstrand L. 
Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced 
autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine 
phosphatase SHP2. Blood. 2006;108:1542-50 
12. Razumovskaya E, Sun J, Rönnstrand L. Inhibition of MEK5 by BIX02188 induces 
apoptosis in cells expressing the oncogenic mutant FLT3-ITD. Biochem Biophys Res 
Commun. 2011;412:307-12. 
13. Pradhan A, Lambert QT, Reuther GW. Transformation of hematopoietic cells and 
activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine 
receptor. Proc Natl Acad Sci U S A. 2007;104:18502-7 
14. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed 
repair of DNA damage in mammalian cells. Genes Dev. 1999;13:2633-8. 
15. Richardson C, Moynahan ME, Jasin M. Double-strand break repair by interchromosomal 
recombination: suppression of chromosomal translocations. Genes Dev. 1998;12:3831-42. 
16. Luria SE, Delbrück M. Mutations of Bacteria from Virus Sensitivity to Virus Resistance. 
Genetics. 1943;28:491-511. 
17. Seedhouse CH, Hunter HM, Lloyd-Lewis B, Massip AM, Pallis M, Carter GI, Grundy M, 
Shang S, Russell NH. DNA repair contributes to the drug-resistant phenotype of primary 
acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the 
FLT3 inhibitor PKC412. Leukemia. 2006;20:2130-6 
22 
 
18. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated levels of 
RAD51 recombination protein in tumor cells. Cancer Res. 2002;62:219-225  
19. Marty C, Lacout C, Droin N, Le Couédic JP, Ribrag V, Solary E, et al. A role for reactive 
oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia. 2013. 
27:2187-95 
20. Skopek TR, Liber HL, Penman BW, Thilly WG. Isolation of a human lymphoblastoid line 
heterozygous at the thymidine kinase locus: possibility for a rapid human cell mutation 
assay.. Biochem. Biophys. Res. Commun. 1978;84:411-416.  
21. Zeigler FC, Bennett BD, Jordan CT, Spencer SD, Baumhueter S, Carroll KJ, et al. 
Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in 
hematopoietic stem cells. Blood. 1994;84:2422-30. 
22. Lee BH, Tothova Z, Levine RL, Anderson K, Buza-Vidas N, Cullen DE, et al. FLT3 
mutations confer enhanced proliferation and survival properties to multipotent progenitors in 
a murine model of chronic myelomonocytic leukemia. Cancer Cell. 2007;12:367-80. 
23. Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, et al. 
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. 
Leukemia. 2008;22:87-95 
24. Mohamedali A, Gäken J, Twine NA, Ingram W, Westwood N, Lea NC, et al. Prevalence 
and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis 
in low-risk myelodysplastic syndromes. Blood. 2007;110:3365-73. 
25. Gaymes TJ, Mohamedali AM, Patterson M, Matto N, Smith A, Kulasekararaj A, et al. 
Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer 
hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. 
Haematologica. 2013;98:1397-406. 
23 
 
26. Melcher R, Al-Taie O, Kudlich T, Hartmann E, Maisch S, Steinlein C, et al. SNP-Array 
genotyping and spectral karyotyping reveal uniparental disomy as early mutational event in 
MSS- and MSI-colorectal cancer cell lines. Cytogenet Genome Res. 2007;118:214-21. 
27. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms 
of blastic transformation. J Clin Invest. 2010;120:2254-64. 
28. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim 
Biophys Acta. 2011;1813:1978-86. 
29. Klein HL. The consequences of Rad51 overexpression for normal and tumor cells. DNA 
Repair. 2008;7:686-93 
30. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y et al. Effective elimination of 
fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 
2008;112:1912-22 
  
24 
 
Table I. Summary of iHR mediated events in mutant FLT3-ITD and JAK2V617F cells. Percentages 
are the result of replicate studies, (n=3) 
  
 Targeted iHR 
(Mean %  SEM GFP cells) 
Cell Untreated  + 25nM 
AC220 
+ 5mM 
NAC 
+ 25µM 
B02 
+ 50µM 
H2O2 
      
MOLM-13PZD 0.15  0.05 0 0 0 0.25  0.05 
U937PZD 0 0 0 0 0 
HEK293PZD + 
EV 
0 0 0 0 0 
HEK293PZD + 
WT FLT3  
0 0 0 0 0 
HEK293PZD + 
FLT3-ITD   
0.25 0.05 0 0 0 0.4 0.05 
      
HELPZD 0.2 0.05 0 0 0 0.15 
HEK293PZD +   
WT JAK2 
0 0 0 0 0 
HEK293PZD + 
JAK2V617F 
0.3  0.05 0 0 0 0.4 0.05 
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Figure Legends 
1. Zinc Finger Nuclease (ZFN) targeted assay for iHR demonstrates increased iHR in FLT3-
ITD mutated cells. A-B, Maps of targeting vectors. A, PZDonor-AAVS1 Puromycin, B, 
PZDonor. HA – homology arm. C, DR1 insert possesses a 5’ GFP sequence interrupted by 
an 18bp recognition sequence for I-SCEI. DR1 insert was cloned into the MCS of pZDonor-
AAVS puromycin vector to create PZD-DR1-Puro. D, DR2-BLAST insert possesses a 
truncated 3’ GFP sequence. The construct was cloned into the MCS of pZDonor to create 
PZD-DR2-Blast. E, To confirm PZD-DR1-Puro and PZD-DR2-Blast integration at separate 
AAVS1 loci, vector and ZFN transfected cells were aliquoted into 24 well plates and 
individually checked for integration using PCR with vector and locus specific primers. Correct 
integration would produce a PCR product for PZD-DR1-Puro of 2300bp (upper panel) and 
PZD-DR2-Blast of 2100bp (bottom panel). F,G Co-FISH using a fluorescein labelled PZD-
DR1-Puro (green) and Texas Red labelled PZD-DR2-Blast. Probes were sequentially 
hybridised to (F) DAPI stained cells and (G) metaphase chromosomes. Original 
magnification X 100. H, FACS analysis of MOLM-13PZD, MOLM-13PZD pre-treated with 
25nM AC220 and FLT3-ITD transfected HEK293PZD. To determine GFP recombination 
events, cells were analysed using green (FL1) and orange (FL2) filters. Percentage of 
recombined GFP positive cells (recombination events) were made relative to transfection of 
a targeted GFP expressing plasmid. Top panel shows GFP+ve MOLM-13PZD cells, middle 
panel shows GFP+ve MOLM-13PZD cells with prior AC220 addition, bottom panel shows 
FLT3-ITD transfected HEK293PZD GFP+ve cells. I-J, Restriction digest of PZD-DR1-Puro 
PCR products indicates method of repair. Only GFP positive cells would give BCG1 
digestible PCR products. J, PCR products derived from GFP recombined events from 2 
separate experiments were digested with I-SCEI or BCG1. PCR products derived from 
MOLM-13PZD GFP recombination events were digestible with BCG1 and not I-SCEI.  
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2. Mutant FLT3-ITD increases HR activity and events in primary NK-AML. A, FACS analysis 
of PZD-DR1/DR2-Puro targeted cells in primary FLT3-ITD NK-AML (NK4). GFP positive 
cells (recombination events) were analysed using green (FL1) and orange (FL2) filters. 
Recombination events were made relative to transfection of a targeted GFP expressing 
plasmid. B,C Expression of DNA damage and growth signalling proteins were analysed by 
western blotting. Immunoblots were prepared from B) whole cell extracts of primary NK-AML 
(NK4) pre-treated with AC220 for 4h prior to harvest and C) whole cell extracts of transfected 
U937 with WT-FLT3, FLT-ITD or empty vector. Tubulin acted as a loading control. D-F, HR 
repair analysed by immunohistochemistry for phospho-H2AX and RAD51 foci. D, 
Composite figure of foci formation in FLT3-ITD mutated primary NK-AML cells (NK-10). 
Original magnification X 100. E, Frequency of cells displaying greater than 5 foci per cell in 
primary AML. F, Graph of relative ROS % in primary NK-AML. Error bars represent the 
means ± S.E.M. of three separate experiments. G,H SCE analysis of primary NK-AML. G, 
Metaphase spreads of SCE from primary NK-AML cells (NK4). H, Graph of SCE. Error bars 
represent the means ± S.E.M. of three separate experiments. At least 50 cells in metaphase 
were counted per test. Error bars represent the means ± S.E.M. of three separate 
experiments. Original magnification X 100. 
3. Mutant JAK2V617F confers iHR associated with increased HR activity and ROS. A-B, 
RAD51 expression by Q-PCR and western blotting in HEL (JAK2V617F), U937 (WT JAK2), 
HEK293 (WT JAK2) + Empty vector (EV), HEK293 + WT JAK2, HEK293 + JAK2V617F. A, 
cDNA relative target abundance (fold change) was normalized against the house-keeping 
genes GAPDH, Tubulin and B2M and then normalized to JAK2 expression. B, Immunoblots 
were prepared from whole cell extracts of HEL cells and WT-JAK2, JAK2V617F or empty 
vector transfected HEK293. Tubulin acted as a loading control. C,D iHR and HR activity in 
JAK2V617F mutated cells. C, iHR events in JAK2V617F transfected HEK293PZD. Cells 
were pre-treated with NAC where indicated for 5 days prior to analysis. Left panel shows 
GFP+ve cells without NAC, right panels show GFP+ve cells with NAC pre-treatment.  D, HR 
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events in PZD-DR1/DR2-Puro targeted cells HEL cells (upper panel) and JAK2V617F 
transfected HEK293 (lower panel). To determine DR-GFP recombination events, cells were 
analysed using green (FL1) and orange (FL2) filters. Percentage of recombined GFP 
positive cells (recombination events, inset %) was made relative to transfection of a targeted 
GFP expressing plasmid. E, Frequency of cells displaying greater than 5 foci per cell and D, 
number of foci per cell for RAD51 foci (%) (Red bars) in primary cells and transfected cell 
lines.  200 nuclei were counted per experiment. Error bars represent the means ± S.E.M. of 
three separate experiments. F, Graph of relative ROS % in WT JAK2 or JAK2V617F cells. 
Error bars represent the means ± S.E.M. of three separate experiments.  
4. G0 arrested FLT3-ITD mutants demonstrate RAD51 expression and significant HR 
activity. A,B Composite representation of RAD51 foci in A, G0 arrested primary FLT3-ITD 
NK-AML and B, G0 arrested primary WT FLT3 NK-AML by immunocytochemistry. Original 
magnification X 40. C,D Identification of RAD51 expression in C, G0 arrested primary NK- 
FLT3-ITD AML and D, G0 arrested primary WT FLT3 NK-AML by western blotting. 
Immunoblots were prepared from whole cell extracts of primary NK-AML and probed with 
anti-RAD51. Tubulin acted as a loading control. E, Cell cycle kinetics of G0 arrested MOLM-
13 and U937. Arrested cells determined as G0 phase (histogram peak and dot plot bottom 
left quadrant cells (insert)) were collected by FACS sorting. F. G0 and S/G2 FACS sorted 
cells were analysed for RAD51 expression by western blotting in MOLM-13 and U937. 
Tubulin acted as a loading control. G, FACS analysis of PZD-DR1/DR2-Puro transfected G0 
arrested MOLM-13 with and without prior treatment with AC220 or NAC. To determine HR 
events, cells were analysed using green (FL1) and orange (FL2) filters. Percentage of 
recombined GFP positive cells (recombination events) was made relative to transfection of a 
targeted GFP expressing plasmid. 
5. Spontaneous thymidine kinase (TK) mutation rate and frequencies of TK6 cells 
transfected with FLT3-ITD and WT FLT3 expressing vectors or controls. A, Mutation rate 
and frequencies in transfected TK6 cells treated with and without AC220 or NAC. Error bars 
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represent the means ± S.E.M. of three separate experiments. B, Mutation spectrum at the 
TK locus. Fragment fluorescent PCR was used to determine the presence of LOH. Mutants 
with double peaks (left panel) for each exon were considered wild type at the TK locus. 
Mutants with single peaks have LOH. Comparison of peak areas relative to the peak area for 
-globin can be used to distinguish copy neutral LOH (CN-LOH) and hemizygous LOH. CN-
LOH (right panel) will have double peak area compared to hemizygous LOH. C, Graph of 
CN-LOH TK mutants from transfected TK6 treated with and without AC220 or NAC. Error 
bars represent the means ± S.E.M. of three separate experiments. D, Determination of CN-
LOH regions at the TK locus. Fluorescent fragment PCR of heterologous microsatellites at 
the TK locus were analysed to determine the extent of LOH in FLT3-ITD TK mutant clones. 
Approximate position of each microsatellite is stated. Human TK locus maps to 17q25. 
Length of bars indicates size of CN-LOH at the TK locus. E, Proposed model of the 
collaborative activities of ROS and HR to create CN-LOH in mutated FLT3 myeloid 
malignancy.  
 
 
